Dark

Check out our Dark Pool Levels

BPTH
BIO-PATH HOLDINGS INC
stock OTC

EOD

Mar 13, 2026

0.0654USD-5.116%(-0.0035)30,017

Pre-market

0.00USD-100.000%(-0.07)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 5, 2022

07:00AM EST Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 GlobeNewswire Inc

Dec 13, 2021

07:14AM EST Bio-Path Holdings Presents Data From Ongoing Phase 2 Study Of Prexigebersen At 2021 American Society of Hematology Annual Meeting Benzinga

07:00AM EST Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of GlobeNewswire Inc

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Nov 12, 2021

07:30AM EST Bio-Path Holdings Q3 EPS $(0.29) Beats $(0.36) Estimate Benzinga

07:00AM EST Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2021 and provided an update on recent corporate developments. GlobeNewswire Inc

04:26AM EST Earnings Scheduled For November 12, 2021 Benzinga

Nov 5, 2021

08:00AM EDT Bio-Path Holdings to Announce Third Quarter 2021 Financial Results GlobeNewswire Inc

Oct 27, 2021

07:34AM EDT Bio-Path Holdings Announces Clearance Of Investigational New Drug Application For Phase 1/1b Clinical Trial Of Prexigebersen-A In Solid Tumors Benzinga

07:00AM EDT Bio-Path Holdings Announces Clearance of Investigational New Drug GlobeNewswire Inc

Aug 25, 2021

06:05AM EDT Mid-Day Market Update: Crude Oil Rises Over 2%; Theravance Biopharma Shares Slide Benzinga

06:05AM EDT Mid-Morning Market Update: Markets Edge Higher; Best Buy Earnings Top Estimates Benzinga

Aug 24, 2021

12:18PM EDT Mid-Day Market Update: Crude Oil Rises Over 2%; Theravance Biopharma Shares Slide Benzinga

11:00AM EDT Why Bio-Path Holdings Shares Are Surging Higher Today Benzinga

10:13AM EDT Mid-Morning Market Update: Markets Edge Higher; Best Buy Earnings Top Estimates Benzinga

08:17AM EDT Benzinga Pro's Top 4 Stocks To Watch For Tuesday, Aug. 24, 2021: NVDA, SPLK, LOOP, BPTH Benzinga

08:09AM EDT The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal Benzinga

07:40AM EDT Biotechnology company Bio-Path Holdings, Inc. (BPTH) announced Monday that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Investigational New Drug (IND) application for BP1002 (liposomal Bcl-2), the Company's second drug candidate. RTTNews

07:14AM EDT Bio-Path: FDA Clears IND Application For BP1002 In R/r Acute Myeloid Leukemia Patients RTTNews

07:09AM EDT Bio-Path Holdings Announces FDA Clearance Of Investigational New Drug Application For BP1002 In Refractory/Relapsed Acute Myeloid Leukemia Patients Benzinga

07:00AM EDT Bio-Path Holdings Announces Clearance of Investigational New Drug GlobeNewswire Inc

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

07:17AM EDT Bio-Path Holdings Q2 EPS $(0.26) Beats $(0.39) Estimate Benzinga

07:00AM EDT Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2021 and provided an update on recent corporate developments. GlobeNewswire Inc

04:12AM EDT Earnings Scheduled For August 13, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 6, 2021

07:00AM EDT Bio-Path Holdings to Announce Second Quarter 2021 Financial GlobeNewswire Inc

Jun 22, 2021

10:36AM EDT Shares of Bio-Path Holdings, Inc. (BPTH) are up more than 6% Tuesaday morning after the company announced that the United States Patent and Trademark Office has granted a new patent relating to the company's BP1003 program. RTTNews

07:21AM EDT Bio-Path Holdings Says USPTO Granted New Patent Relating To BP1003 Program RTTNews

07:09AM EDT Bio-Path Granted Mechanism Of Action US Patent For BP1003 Benzinga

07:00AM EDT Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003 GlobeNewswire Inc

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

07:06AM EDT Bio-Path Holdings Q1 Loss/Shr $0.43 Vs Loss $0.90 Prior Year RTTNews

07:00AM EDT Bio-Path Holdings Q1 EPS $(0.43) Beats $(0.49) Estimate Benzinga

07:00AM EDT Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent corporate developments. GlobeNewswire Inc

04:03AM EDT Earnings Scheduled For May 14, 2021 Benzinga

May 7, 2021

07:00AM EDT Bio-Path Holdings to Announce First Quarter 2021 Financial Results GlobeNewswire Inc

Apr 29, 2021

12:46PM EDT Bio-Path Holdings Granted U.S. Patent Titled 'P-ETHOXY NUCLEIC ACIDS FOR BCL2 INHIBITION' Benzinga

Apr 22, 2021

07:00AM EDT Bio-Path Announces Publication in Biomedicines GlobeNewswire Inc

Apr 12, 2021

07:03AM EDT Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting Benzinga

07:00AM EDT Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces the presentation of a poster highlighting preclinical BP1002 data at the 2021 American Association for Cancer Research (AACR) Annual Meeting. GlobeNewswire Inc

Apr 5, 2021

08:03AM EDT Bio-Path Stock Is Trading Higher As Prexigebersen Triplet Combo Shows Favorable Safety Profile In Acute Myeloid Leukemia Study Benzinga

07:03AM EDT Bio-Path Holdings Completes Safety Cohort Of Triple Combination Of Prexigebersen, Decitabine And Venetoclax In Stage 2 Of Phase 2 Clinical Trial In Acute Myeloid Leukemia; Five Patients Responded To Treatment Benzinga

07:00AM EDT Bio-Path Holdings Announces Successful Completion of Safety Cohort GlobeNewswire Inc

Mar 11, 2021

10:02AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 11, 2021 Benzinga

07:33AM EST Roth Capital Initiates Coverage On Bio-Path Holdings with Buy Rating, Announces Price Target of $13 Benzinga

07:03AM EST Bio-Path Holdings To Present At 2021 American Association For Cancer Research Annual Meeting Apr. 10 Benzinga

07:00AM EST Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming virtual poster presentation at the 2021American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15 and May 17-21, 2021. GlobeNewswire Inc

Mar 10, 2021

07:26AM EST The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link Benzinga

07:01AM EST Bio-Path Holdings Reports FY20 EPS $(2.83) Up From $(3.24) YoY Benzinga

07:00AM EST Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the year ended December 31, 2020 and provided an update on recent corporate developments. GlobeNewswire Inc

04:04AM EST Earnings Scheduled For March 10, 2021 Benzinga

Mar 6, 2021

10:58AM EST The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings Benzinga

Mar 3, 2021

04:01PM EST Bio-Path Holdings to Announce Full Year 2020 Financial Results on GlobeNewswire Inc

Feb 23, 2021

06:26AM EST Bio-Path Holdings Issued U.S. Patent #10,927,379 ''Combination therapy with liposomal antisense oligonucleotides' Benzinga

Feb 22, 2021

10:03AM EST Bio-Path Holdings Receives Notice Of Allowance For U.S. Patent Application Titled 'P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION' Benzinga

Feb 18, 2021

04:01PM EST Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public GlobeNewswire Inc

Feb 16, 2021

07:18AM EST Bio-Path Holdings Prices 1,710,600 Share Common Stock Offering At $7.60/Share Benzinga

07:15AM EST Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public GlobeNewswire Inc

Feb 13, 2021

07:00AM EST Bio-Path Holdings, Inc. Announces Proposed Public Offering of GlobeNewswire Inc

Feb 10, 2021

03:12PM EST Mid-Afternoon Market Update: Dow Surges Over 100 Points; Panbela Therapeutics Shares Plunge Benzinga

03:11PM EST Mid-Day Market Update: US Stocks Turn Lower; Bio-Path Shares Jump Benzinga

09:58AM EST Shares of Bio-Path Holdings, Inc. (BPTH) are surging more than 295% Wednesday morning on the news of it receiving third U.S. patent related to manufacture of platform technology. RTTNews

07:08AM EST Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology Benzinga

07:00AM EST Bio-Path Receives Third U.S. Patent Grant Related to Manufacture GlobeNewswire Inc

Jan 26, 2021

06:12AM EST Bio-Path Holdings Issued U.S. Patent #10,898,506 'P-ethoxy nucleic acids for liposomal formulation' Benzinga

Nov 19, 2020

07:21AM EST Bio-Path Reports Enrollment And Dosing Of First Patient In Phase 1 Clinical Trial On BP1002 RTTNews

07:00AM EST Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002 Benzinga

07:00AM EST Bio-Path Holdings Announces First Patient Dosed in Phase 1 GlobeNewswire Inc

Nov 16, 2020

08:12AM EST 10 Biggest Price Target Changes For Monday Benzinga

06:27AM EST HC Wainwright & Co. Maintains Buy on Bio-Path Holdings, Lowers Price Target to $10 Benzinga

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

07:27AM EST Bio-Path Holdings Q3 Net Loss $3.0 Mln Or $0.80/Shr Vs Net Loss $2.2 Mln Or $0.78/Shr Last Year RTTNews

07:04AM EST Bio-Path Holdings Late Thursday Reported Q3 EPS $(0.80) Beats $(0.87) Estimate Benzinga

07:00AM EST Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2020 and provided an update on recent corporate developments. GlobeNewswire Inc

04:18AM EST Earnings Scheduled For November 13, 2020 Benzinga

Nov 6, 2020

08:00AM EST Bio-Path Holdings to Announce Third Quarter 2020 Financial Results GlobeNewswire Inc

Oct 22, 2020

02:35PM EDT Mid-Afternoon Market Update: Dow Jumps 200 Points; Align Technology Shares Climb After Q3 Results Benzinga

12:49PM EDT Mid-Day Market Update: Crude Oil Rises 2%; InVivo Therapeutics Shares Plummet Benzinga

10:15AM EDT Shares of Bio-Path Holdings, Inc. (BPTH) are gaining more than 22 percent or $0.93 in Thursday's morning trade at $5.04. RTTNews

07:08AM EDT Bio-Path Reports Notice Of Allowance For Strategic Patent For Prexigebersen In Combo With Front Line Cytidine Analogues Or Bcf-Abl Tyrosine Kinase Inhibitors In a Variety Of Cancers Benzinga

07:00AM EDT Bio-Path Receives Notice of Allowance for Strategic Patent for GlobeNewswire Inc

Sep 9, 2020

08:00AM EDT Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual GlobeNewswire Inc

Aug 21, 2020

10:49AM EDT Bio-Path Holdings Shares Resume Trading; Up 30% Benzinga

10:45AM EDT Bio-Path Holdings Shares Halted On Volatility Benzinga

Aug 14, 2020

08:26AM EDT The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal Benzinga

07:11AM EDT Bio-Path Q2 Net Loss $2.0 Mln Or $0.55/Shr Vs Loss Of $2.5 Mln Or $0.87/Shr Last Year RTTNews

07:07AM EDT Bio-Path Holdings Reported Late Thurs. Q2 EPS $(0.55) Beats $(0.96) Estimate Benzinga

07:00AM EDT Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2020 and provided an update on recent corporate developments. GlobeNewswire Inc

Aug 13, 2020

07:10AM EDT Bio-Path Reports First Patient Dosed In Amended Stage 2 Of Phase 2 Trial Evaluating Prexigebersen In Acute Myeloid Leukemia Benzinga

07:00AM EDT Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 GlobeNewswire Inc

Aug 7, 2020

08:00AM EDT Bio-Path Holdings to Announce Second Quarter 2020 Financial GlobeNewswire Inc

Share